Antiplatelet drug

Antiplatelet Drug

Antiplatelet drugs are a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. They are effective in the arterial circulation, where anticoagulants have little effect. These drugs are commonly used in the prevention and treatment of cardiovascular diseases, such as myocardial infarction, stroke, and peripheral artery disease.

Mechanism of Action

Antiplatelet drugs work by interfering with the platelet activation and aggregation processes. Platelets play a crucial role in hemostasis, and their aggregation is a key step in the formation of a thrombus. The main mechanisms by which antiplatelet drugs exert their effects include:

• Inhibition of Cyclooxygenase (COX): Drugs like aspirin inhibit the enzyme cyclooxygenase, which is necessary for the synthesis of thromboxane A2, a potent promoter of platelet aggregation.

• ADP Receptor Inhibition: Drugs such as clopidogrel, prasugrel, and ticagrelor block the P2Y12 component of the ADP receptor on the platelet surface, preventing ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, which is essential for platelet aggregation.

• Glycoprotein IIb/IIIa Inhibition: Agents like abciximab, eptifibatide, and tirofiban directly inhibit the glycoprotein IIb/IIIa receptor, preventing fibrinogen binding and cross-linking of platelets.

Clinical Uses

Antiplatelet drugs are primarily used in the following clinical scenarios:

• Acute Coronary Syndrome (ACS): Antiplatelet therapy is a cornerstone in the management of ACS, including unstable angina and myocardial infarction.

• Secondary Prevention of Cardiovascular Events: Patients with a history of myocardial infarction, ischemic stroke, or established peripheral artery disease benefit from long-term antiplatelet therapy to prevent recurrent events.

• Percutaneous Coronary Intervention (PCI): Antiplatelet drugs are used to prevent thrombotic complications following PCI, including stent thrombosis.

Side Effects

Common side effects of antiplatelet drugs include:

• Bleeding: The most significant risk associated with antiplatelet therapy is bleeding, which can range from minor bruising to major hemorrhagic events.

• Gastrointestinal Issues: Aspirin, in particular, can cause gastrointestinal irritation and ulcers.

• Hypersensitivity Reactions: Some patients may experience allergic reactions to antiplatelet medications.

Contraindications

Antiplatelet drugs are contraindicated in patients with:

• Active bleeding or bleeding disorders
• Severe liver disease
• Known hypersensitivity to the drug

Also see

• Anticoagulant
• Thrombolytic therapy
• Cardiovascular disease
• Stroke prevention

Cardiovascular disease A-Z

Most common cardiac diseases

• Cardiac arrhythmia‎
• Cardiogenetic disorders‎
• Cardiomegaly‎
• Cardiomyopathy‎
• Cardiopulmonary resuscitation‎
• Chronic rheumatic heart diseases‎
• Congenital heart defects‎
• Heart neoplasia‎
• Ischemic heart diseases‎
• Pericardial disorders
• Syndromes affecting the heart‎
• Valvular heart disease‎

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

A

• Accelerated idioventricular rhythm
• Acute decompensated heart failure
• Arteriosclerotic heart disease
• Athletic heart syndrome
• Atrial flutter
• Atrioventricular fistula
• Cardiovascular disease in Australia
• Autoimmune heart disease

B

• Brown atrophy of the heart

C

• Ebb Cade
• Cardiac allograft vasculopathy
• Cardiac amyloidosis
• Cardiac asthma
• Cardiac tamponade
• Cardiogenic shock
• Cardiogeriatrics
• Cardiorenal syndrome
• Cardiotoxicity
• Carditis
• Coronary artery aneurysm
• Coronary artery anomaly
• Coronary artery disease
• Spontaneous coronary artery dissection
• Coronary artery ectasia
• Coronary occlusion
• Coronary steal
• Coronary thrombosis
• Coronary vasospasm
• Cœur en sabot
• Coxsackievirus-induced cardiomyopathy

D

• Duke Treadmill Score
• Duroziez's disease

E

• Eisenmenger's syndrome
• Embryocardia
• Endocardial fibroelastosis
• Eosinophilic myocarditis

H

• Heart attack
• Heart failure
• Heart failure with preserved ejection fraction
• Heart to Heart (1949 film)
• High-output heart failure
• Hyperdynamic precordium

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

I

• Idiopathic giant-cell myocarditis
• Interventricular dyssynchrony
• Intraventricular dyssynchrony
• Isolated atrial amyloidosis

K

• Keshan disease

L

• Loeffler endocarditis

M

• Mydicar
• Myocardial bridge
• Myocardial disarray
• Myocardial rupture
• Myocardial scarring
• Myocardial stunning
• Myocarditis

N

• Nonbacterial thrombotic endocarditis

O

• OLR1
• Ostial disease

P

• Papillary fibroelastoma
• Pathophysiology of heart failure
• Postpericardiotomy syndrome
• Pulmonary vein stenosis

R

• Right axis deviation
• Roemheld syndrome

S

• Saturated fat and cardiovascular disease
• SCAR-Fc
• Shone's syndrome
• Strain pattern
• Subacute bacterial endocarditis
• Sudden cardiac death of athletes

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

T

• Traumatic cardiac arrest

V

• Ventricular aneurysm
• Vibroacoustic disease
• Viral cardiomyopathy

W

• Waon therapy